207 related articles for article (PubMed ID: 19863538)
1. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
Patel B; Rai L; Buck G; Richards SM; Mortuza Y; Mitchell W; Gerrard G; Moorman AV; Duke V; Hoffbrand AV; Fielding AK; Goldstone AH; Foroni L
Br J Haematol; 2010 Jan; 148(1):80-9. PubMed ID: 19863538
[TBL] [Abstract][Full Text] [Related]
2. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
4. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
5. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
6. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
[TBL] [Abstract][Full Text] [Related]
7. Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.
Gidman W; Shah S; Zhang L; McKendrick J; Cong Z; Cohan D; Ottmann O
Adv Ther; 2019 Nov; 36(11):3017-3029. PubMed ID: 31586302
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
10. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Bonifacio M; Reichle A; Graux C; Faul C; Diedrich H; Topp MS; Brüggemann M; Horst HA; Havelange V; Stieglmaier J; Wessels H; Haddad V; Benjamin JE; Zugmaier G; Nagorsen D; Bargou RC
Blood; 2018 Apr; 131(14):1522-1531. PubMed ID: 29358182
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.
Mortuza FY; Papaioannou M; Moreira IM; Coyle LA; Gameiro P; Gandini D; Prentice HG; Goldstone A; Hoffbrand AV; Foroni L
J Clin Oncol; 2002 Feb; 20(4):1094-104. PubMed ID: 11844835
[TBL] [Abstract][Full Text] [Related]
15. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Giebel S; Bruggemann M; Doubek M; Foà R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Rambaldi A; Ribera JM; Schoonen M; Stieglmaier JM; Zugmaier G; Bassan R
Hematology; 2019 Dec; 24(1):337-348. PubMed ID: 30757960
[TBL] [Abstract][Full Text] [Related]
17. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
18. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
